AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding AARD investors of a securities class action and a lead plaintiff deadline of October 13, 2026. The complaint alleges Aardvark misled investors about the safety profile and clinical and commercial prospects of its ARD-101 drug candidate around the February 13, 2025 IPO, with a class period through May 14, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.